Uniqure Plummets 35% On Another Shocking Twist For Its Huntington's Drug

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease. The post Uniqure Plummets 35% On Another Shocking Twist For Its Huntington's Drug appeared first on Investor's Business Daily.